[ET Net News Agency, 13 June 2018] Credit Suisse raised its target price for 3SBio Inc.
(01530) to HK$21.3 from HK$17.8, and retained its "neutral" rating.
The research house said 3SBio management attended Credit Suisse's Healthcare Corporate
Day last week. Management maintained its original guidance of 20-30% top line growth this
year, despite TPIAO already having achieved 60% growth year-to-date according to sample
sales data.
Credit Suisse raised 3SBio's EPS forecasts by 3%/6% in 2018/19 to factor in
stronger-than-expected TPIAO sales growth. It believes the current price already factors
in near-term growth, and the company's pipeline is thin in the near to mid-term. (KL)